Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: obser-vational, prospective study in primary care

References

• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-71
   PubMed Web of Science ®Google Scholar
• Guidelines committee. European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Glaesmer H, Marz W, et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates – the DETECT program. Curr Med Res Opin 2005;21:619-30
   PubMed Web of Science ®Google Scholar
• Krone W, Böhm M, Wöhrmann A, et al. Erhebung und Verbesserung der Behandlungssituation von Patienten mit Diabetes mellitus. Das DUTY-Register. Bundesgesundheits-blatt – Gesundheitsforschung – Gesundheitsschutz 2004;47:540-6
   PubMedGoogle Scholar
• Voller H, Sonntag FJ, Thiery J, et al. Management of high-risk patients with hypertension and left ventricular hypertrophy in Germany: differences between cardiac specialists in the inpatient and outpatient setting. BMC Public Health 2006;6:256
   PubMed Web of Science ®Google Scholar
• Wong ND, Lopez VA, L'Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 2007;167:2431-6
   PubMed Web of Science ®Google Scholar
• Epstein M, Sowers J. Diabetes mellitus and hypertension. Hypertension 1992;19:403-18
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Diabetes and Hypertension. Diabetes Care 2001;24:1679-84
   PubMed Web of Science ®Google Scholar
• Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006;69:2057-63
   PubMed Web of Science ®Google Scholar
• Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005;111:1370-6
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Schrader J, Zidek W, et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007;96:247-57
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Federal Institute for Medicinal Products and Medical Devices. German Drug Law (Arzneimittelgesetz - AMG) of the Federal Republic of Germany. Available at: http://www.bfarm.de/cln_030/nn_891668/SharedDocs/Publikationen/EN/BfArM/service/AMG__en,templateId=raw,property=publicationFile.pdf/AMG_en.pdf [Last accessed 9 February 2009]
   Google Scholar
• Federal Institute for Medicinal Products and Medical Devices (BfArM). Recommendations for the Planning, Execution and Evaluation of Post-Marketing Surveillance Studies (Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln – Empfehlungen zur Planung und Durchführung von Anwendungsbeobachtungen). Bonn, 1998. Available at: http://www.dzkf.de/heft/1999_1-2/AWBs.htm [Last accessed 9 February 2009]
   Google Scholar
• German Association of Research-based Pharmaceutical Companies (Verband der forschenden Arzneimittelhersteller VfA). Rules for publication of post-marketing surveillance studies. Available at: http://www.vfa.de/en/articles/art-2007-11-002.html [Last accessed 9 February 2009]
   Google Scholar
• Fernandez Fernandez I, Paez Pinto J, Hermosin Bono T, et al. Rapid screening test evaluation for microalbuminuria in diabetes mellitus. Acta Diabetol 1998;35:199-202
   PubMed Web of Science ®Google Scholar
• Piehlmeier W, Renner R, Schramm W, et al. Screening of diabetic patients for microalbuminuria in primary care – The PROSIT-Project. Proteinuria Screening and Intervention. Exp Clin Endocrinol Diabetes 1999;107:244-51
   PubMed Web of Science ®Google Scholar
• Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-17
   PubMed Web of Science ®Google Scholar
• Naidoo DP, Sareli P, Marin F, et al. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther 1999;16:187-99
   PubMed Web of Science ®Google Scholar
• Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001;23:1193-208
   PubMed Web of Science ®Google Scholar
• Gradman AH, Brady WE, Gazdick LP, et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002;24:1049-61
   PubMed Web of Science ®Google Scholar
• Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004;6:614-20
   PubMedGoogle Scholar
• Oparil S, Aurup P, Snavely D, et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001;87:721-6
   PubMed Web of Science ®Google Scholar
• Coca A, Sobrino J, Soler J, et al. Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. J Cardiovasc Pharmacol 2002;39:824-33
   PubMed Web of Science ®Google Scholar
• Förster A, Smolka W, Jung C, et al. Fixed-dose combination of losartan/hydrochlorothiazide 100mg/25mg: safety and efficacy on office and 24-h blood pressure [German]. MMW Fortschr Med 2007;149:111-18
   PubMedGoogle Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   Google Scholar
• Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003;21:797-804
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
   PubMed Web of Science ®Google Scholar
• Lubsen J, Wagener G, Kirwan B, et al. ACTION (A Coronary disease Trial Investigating Outcome with Niefedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005;23:642-8
   Google Scholar
• Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25
   PubMed Web of Science ®Google Scholar
• Diehm CD, Pittrow D, Allenberg J, et al. Metabolic syndrome and peripheral arterial disease as indicators for increased cardiovascular risk [German]. Deutsche Med Wochenschr 2007;132:15-20
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24:1201-8
   PubMed Web of Science ®Google Scholar
• O'Connor PJ. Overcome clinical inertia to control systolic blood pressure. Arch Intern Med 2003;163:2677-8
   PubMed Web of Science ®Google Scholar
• Phillips L, Branch W, Cook C, et al. Clinical inertia. Ann Intern Med 2001;135:825-34
   PubMed Web of Science ®Google Scholar
• Bestehorn K, Smolka W, Schmieder R, et al. Improvement of hypertension management by structured physician education and feedback system: cluster randomised trial. Internal study report, 2 February 2008. MSD Haar, Germany
   Google Scholar
• Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004;60:135-42
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J 2003;326:1427-40
   PubMed Web of Science ®Google Scholar
• Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care. Curr Med Res Opin 2004;20:1625-31
   PubMed Web of Science ®Google Scholar
• Moen MD, Wagstaff AJ. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005;65:2657-74
   PubMed Web of Science ®Google Scholar
• Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999;159:551-8
   PubMed Web of Science ®Google Scholar
• Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000;139:174-83
   PubMed Web of Science ®Google Scholar